AstraZeneca: good results in prostate cancer

(CercleFinance.com) - A phase III clinical trial has shown that Lynparza, the anti-cancer drug developed by AstraZeneca and Merck, "significantly" improved progression-free survival in patients with prostate cancer.


The trial showed that Lynparza, combined with abiraterone, a standard treatment for the disease, reduced the risk of worsening or death by 34% compared to abiraterone alone.

The combination of these drugs also improved the median progression-free survival time by 24.8 months, compared to 16.6 months for abiraterone.

The study was conducted in the first-line treatment of patients with metastatic castration-resistant prostate cancer with or without confirmed LHRH receptors.

The results were published in the New England Journal of Medicine (NEJM).


Copyright (c) 2022 CercleFinance.com. All rights reserved.